Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 570 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Product E Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

NCT03890302
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
FB704A, Placebo
Drug
Lead sponsor
Fountain Biopharma Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 17, 2026, 1:11 PM EDT
Terminated Phase 2 Interventional Results available

A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ

NCT01060345
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Polyphenon E
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 17, 2026, 1:11 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Daratumumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
26
States / cities
Clovis, California • Fresno, California • Fort Collins, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 17, 2026, 1:11 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking

NCT06922617
View directory record Official record
Conditions
Tobacco Use, Substance Use Disorders
Interventions
Switching to E-Cigarette, Quitting using Medication, Counseling
Behavioral · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
4
States / cities
Charleston, South Carolina • Conway, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention

NCT03855410
View directory record Official record
Conditions
Tobacco Use, Drug Use, Adolescent Behavior, Alcohol Use, Sexual Risk Behavior
Interventions
S4E, Attention-Matched Control Group
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Ann Arbor, Michigan • Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 17, 2026, 1:11 PM EDT
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparative Abuse Liability Among African American and White Smokers

NCT04646668
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
E-cigarette and Heat not burn
Combination Product
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 17, 2026, 1:11 PM EDT
Terminated Phase 2 Interventional Results available

PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol

NCT03617172
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Misoprostol 100Mcg Tab, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by ENDS Consumers

NCT04620616
View directory record Official record
Conditions
Electronic Cigarette Use
Interventions
RELX ENDS Tobacco Flavor, RELX ENDS Menthol Flavor, Subject Usual Brand ENDS
Other
Lead sponsor
Cheerain HK Limited
Industry
Eligibility
22 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 17, 2026, 1:11 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

TAK-071 Scopolamine-Induced Cognitive Impairment Study

NCT02918266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Methods Project 4: Clinical Trial - Amended

NCT03111537
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Cigarettes, E-Cigarette, Nicotine Gum or Lozenge
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
3
States / cities
Minneapolis, Minnesota • Buffalo, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 1:11 PM EDT
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

NCT03624959
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ozanimod, Gemfibrozil, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 17, 2026, 1:11 PM EDT
Recruiting Phase 2 Interventional

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

NCT04587687
View directory record Official record
Conditions
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Bendamustine Hydrochloride, Brentuximab Vedotin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users

NCT03509285
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Alprazolam Placebo, Cenobamate placebo, Alprazolam, Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 17, 2026, 1:11 PM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319
View directory record Official record
Conditions
Colorectal Neoplasms, Gastrointestinal Neoplasms
Interventions
JNJ-89402638, Bevacizumab, FOLFOX, FOLFIRI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Tucson, Arizona • Aurora, Colorado • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women

NCT00886834
View directory record Official record
Conditions
Contraception
Interventions
Misoprostol, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

NCT01138072
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2248761, Simvastatin, Atorvastatin, Rosuvastatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Not applicable Interventional Results available

Testing the Effectiveness of a Falls Prevention System

NCT03678402
View directory record Official record
Conditions
High Risk for Falling
Interventions
PUP™ sock
Device
Lead sponsor
Tammy Moore
Other
Eligibility
18 Years and older
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01495702
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
NNRTI, FTC/TDF, Stribild
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
39
States / cities
Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 17, 2026, 1:11 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT07607964
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
ABBV-519
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Anniston, Alabama • Tustin, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Studying Different Formulations of SR13668 in Healthy Volunteers

NCT00896207
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
Akt inhibitor SR13668
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 62 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 17, 2026, 1:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Influence of Electronic (ECIG) Heater Resistance on ECIG Acute Effects

NCT03496116
View directory record Official record
Conditions
Nicotine Dependence
Interventions
ECIG Session
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 17, 2026, 1:11 PM EDT
Recruiting Phase 1 Interventional

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

NCT07484022
View directory record Official record
Conditions
Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Interventions
GB-4362, enfortumab vedotin (EV), Pembrolizumab
Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Duarte, California • Irvine, California • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 1:11 PM EDT